BLRX vs. AKTX, NKGN, PULM, CMMB, LEXX, CYTH, GDTC, ALLK, CDIO, and JATT
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Akari Therapeutics (AKTX), NKGen Biotech (NKGN), Pulmatrix (PULM), Chemomab Therapeutics (CMMB), Lexaria Bioscience (LEXX), Cyclo Therapeutics (CYTH), CytoMed Therapeutics (GDTC), Allakos (ALLK), Cardio Diagnostics (CDIO), and JATT Acquisition (JATT). These companies are all part of the "pharmaceutical products" industry.
BioLineRx vs.
Akari Therapeutics (NASDAQ:AKTX) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings, community ranking and risk.
BioLineRx received 244 more outperform votes than Akari Therapeutics when rated by MarketBeat users. Likewise, 71.77% of users gave BioLineRx an outperform vote while only 50.68% of users gave Akari Therapeutics an outperform vote.
BioLineRx has a consensus target price of $360.00, indicating a potential upside of 9,927.86%. Given BioLineRx's stronger consensus rating and higher possible upside, analysts plainly believe BioLineRx is more favorable than Akari Therapeutics.
5.1% of Akari Therapeutics shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 38.9% of Akari Therapeutics shares are held by company insiders. Comparatively, 1.1% of BioLineRx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, Akari Therapeutics had 3 more articles in the media than BioLineRx. MarketBeat recorded 4 mentions for Akari Therapeutics and 1 mentions for BioLineRx. Akari Therapeutics' average media sentiment score of 0.13 beat BioLineRx's score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the media.
Akari Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -90.57%. Akari Therapeutics' return on equity of 0.00% beat BioLineRx's return on equity.
Akari Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.
Akari Therapeutics has higher earnings, but lower revenue than BioLineRx.
Summary
Akari Therapeutics beats BioLineRx on 8 of the 15 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
This page (NASDAQ:BLRX) was last updated on 2/22/2025 by MarketBeat.com Staff
Free BLRX Stock Alerts